Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

• Published in: Frontiers in neurology Vol. 11; p. 606418
• Main Authors: Alroughani, Raed, Huppke, Peter, Mazurkiewicz-Beldzinska, Maria, Blaschek, Astrid, Valis, Martin, Aaen, Gregory, Pultz, Joe, Peng, Xiaomei, Beynon, Vanessa
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.01.2021
• Subjects: dimethyl fumarate; efficacy; Neurology; pediatric; pharmacokinetics; relapsing-remitting multiple sclerosis; safety; pharmacokinetics; dimethyl fumarate; safety; efficacy; pediatric; relapsing-remitting multiple sclerosis

Background: Pediatric multiple sclerosis (MS) is rare: only 1.5–5% of MS cases are diagnosed before 18 years of age, and data on disease-modifying therapies (DMTs) for pediatric MS are limited. The CONNECTED study assessed the long-term safety and efficacy of treatment with delayed-release dimethyl...